IP Library Granted Patent US 10,227,561
Granted Patent B2
US 10,227,561 · App. 14/930,505 · Granted Mar 12, 2019

Methods and compositions for targeting progenitor cell lines

Inventors: Dana Larocca (Alameda, CA); Paola Bignone (Alameda, CA); Michael D. West (Mill Valley, CA); Evan Snyder (La Jolla, CA)
Assignees: Mandala Biosciences, LLC; BioTime, Inc.; Sanford-Burnham Medical Research Institute
C12N5/0606C07K7/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,227,561
App. No.
14/930,505
Granted
Mar 12, 2019
Kind
B2
Abstract

The invention provides methods, compositions and kits for the identification and enrichment of progenitor cell lines obtained from pluripotent stem cells.

Claims (7)

1. A method of enriching a population of progenitor cells, wherein the progenitor cells are the in vitro progeny of pluripotent stem cells, comprising contacting a population of cells comprising a progenitor cell with a peptide that binds specifically to the progenitor cell, wherein the peptide is chosen from SWTYSYPNQNMD (SEQ ID NO: 1); DWTYSLPGLVEE (SEQ ID NO: 2); NWTWSMPTGNPA (SEQ ID NO: 3); GMTLRVLTN-YTE- (SEQ ID NO: 4); TLHVSENSWTYN (SEQ ID NO: 5); DWLWSFAPNVDT (SEQ ID NO: 6); TLSSQNPYMHKK (SEQ ID NO: 7); IDKQMMTSHKAI (SEQ ID NO: 8); QGMETQKLRMLK (SEQ ID NO: 9); GWYWETPLDMFN (SEQ ID NO: 10); GWVIDYDYYPMR (SEQ ID NO: 11); VTAENYQSFSVS (SEQ ID NO: 12); NNKMDDRMMMSIV (SEQ ID NO: 13); STGTDLHSNARI (SEQ ID NO: 14); YEFDNLLNRTLW (SEQ ID NO: 15); EWTVNERTMWDL (SEQ ID NO: 16), and separating the progenitor cell bound to the peptide from the population of cells thereby enriching for a population of progenitor cells.

2. The method of claim 1 , wherein the progenitor cell is a human cell.

3. The method of claim 2 wherein the progenitor cell is an endoderm cell.

4. The method of claim 2 , wherein the progenitor cell is a mesoderm cell.

5. The method of claim 2 , wherein the progenitor cell is a W10 progenitor cell.

6. The method of claim 1 , wherein the progenitor cell expresses the markers heart and neural crest derivatives-expressed 2 (HAND2), HOXA4 and HOXB7, and wherein the peptide binds specifically to the progenitor cell expressing HAND2, HOXA4 and HOXB7 proteins.

7. The method of claim 1 , wherein the peptide has plexin homology.

Assignments (2)
CHANGE OF NAME Recorded Oct 1, 2020
From: BIOTIME INC.
To: LINEAGE CELL THERAPEUTICS, INC.
Reel/Frame 053955/0779 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2018
From: SNYDER, EVAN
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 047830/0220 →
Continuity (4)
Continuation 13972695 · Aug 21, 2013
Provisional Application 61769119 · Feb 25, 2013
Provisional Application 61692139 · Aug 22, 2012
Related Publication 20170121676A1 · May 4, 2017
Cited By (3)
US 12,404,493 US 12,421,513 US 12,492,400